Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New Frontiers in Hypofractionation for Regional Nodal Irradiation in Breast Cancer

New Frontiers in Hypofractionation for Regional Nodal Irradiation in Breast Cancer Purpose of ReviewIn recent years, there have been a number of small, yet notable practice changes in the delivery of postmastectomy radiation therapy (PMRT) in breast cancer patients. Herein, we describe the role of PMRT and its evolving delivery with hypofractionated regimens.Recent FindingsThe UK START trials and whole-breast hypofractionation studies established the safety and effectiveness of accelerated radiotherapy. This has inspired further investigations of similar principles in patients with reconstruction, acute and late toxicities associated with hypofractionated regimens, socioeconomic benefit, and evolving delivery techniques.SummaryOverall, results from clinical trials evaluating hypofractionation for RNI or PMRT appear promising despite the limited length of follow-up. Ongoing clinical trials will provide valuable data on the safety of hypofractionation in breast cancer patients with immediate reconstruction. Hypofractionation for PMRT represents high-quality care that is not only more convenient for patients but also more cost-effective for the healthcare system. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

New Frontiers in Hypofractionation for Regional Nodal Irradiation in Breast Cancer

Loading next page...
 
/lp/springer-journals/new-frontiers-in-hypofractionation-for-regional-nodal-irradiation-in-A8rVeKFL3A
Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-020-00385-w
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewIn recent years, there have been a number of small, yet notable practice changes in the delivery of postmastectomy radiation therapy (PMRT) in breast cancer patients. Herein, we describe the role of PMRT and its evolving delivery with hypofractionated regimens.Recent FindingsThe UK START trials and whole-breast hypofractionation studies established the safety and effectiveness of accelerated radiotherapy. This has inspired further investigations of similar principles in patients with reconstruction, acute and late toxicities associated with hypofractionated regimens, socioeconomic benefit, and evolving delivery techniques.SummaryOverall, results from clinical trials evaluating hypofractionation for RNI or PMRT appear promising despite the limited length of follow-up. Ongoing clinical trials will provide valuable data on the safety of hypofractionation in breast cancer patients with immediate reconstruction. Hypofractionation for PMRT represents high-quality care that is not only more convenient for patients but also more cost-effective for the healthcare system.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Oct 27, 2020

There are no references for this article.